Logo image of VRAX

VIRAX BIOLABS GROUP LTD (VRAX) Stock Fundamental Analysis

NASDAQ:VRAX - Nasdaq - KYG9495L1251 - Common Stock - Currency: USD

0.98  0 (0%)

Fundamental Rating

3

VRAX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. While VRAX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, VRAX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VRAX has reported negative net income.
VRAX had a negative operating cash flow in the past year.
VRAX had negative earnings in each of the past 5 years.
VRAX had a negative operating cash flow in each of the past 5 years.
VRAX Yearly Net Income VS EBIT VS OCF VS FCFVRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

VRAX has a worse Return On Assets (-69.69%) than 94.12% of its industry peers.
Looking at the Return On Equity, with a value of -76.12%, VRAX is doing worse than 74.51% of the companies in the same industry.
Industry RankSector Rank
ROA -69.69%
ROE -76.12%
ROIC N/A
ROA(3y)-1199.47%
ROA(5y)-1754.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRAX Yearly ROA, ROE, ROICVRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

VRAX has a Gross Margin of 39.58%. This is in the better half of the industry: VRAX outperforms 69.61% of its industry peers.
VRAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRAX Yearly Profit, Operating, Gross MarginsVRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

5

2. Health

2.1 Basic Checks

VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRAX has more shares outstanding
The debt/assets ratio for VRAX is higher compared to a year ago.
VRAX Yearly Shares OutstandingVRAX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
VRAX Yearly Total Debt VS Total AssetsVRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

An Altman-Z score of 3.21 indicates that VRAX is not in any danger for bankruptcy at the moment.
VRAX's Altman-Z score of 3.21 is fine compared to the rest of the industry. VRAX outperforms 69.61% of its industry peers.
VRAX has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.06, VRAX is in the better half of the industry, outperforming 77.45% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 3.21
ROIC/WACCN/A
WACC8.94%
VRAX Yearly LT Debt VS Equity VS FCFVRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 11.58 indicates that VRAX has no problem at all paying its short term obligations.
The Current ratio of VRAX (11.58) is better than 99.02% of its industry peers.
A Quick Ratio of 11.39 indicates that VRAX has no problem at all paying its short term obligations.
VRAX has a Quick ratio of 11.39. This is amongst the best in the industry. VRAX outperforms 99.02% of its industry peers.
Industry RankSector Rank
Current Ratio 11.58
Quick Ratio 11.39
VRAX Yearly Current Assets VS Current LiabilitesVRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.26% over the past year.
VRAX shows a small growth in Revenue. In the last year, the Revenue has grown by 7.06%.
Measured over the past years, VRAX shows a quite strong growth in Revenue. The Revenue has been growing by 9.23% on average per year.
EPS 1Y (TTM)34.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.81%
Revenue 1Y (TTM)7.06%
Revenue growth 3Y9.23%
Revenue growth 5YN/A
Sales Q2Q%-93.46%

3.2 Future

Based on estimates for the next years, VRAX will show a very strong growth in Earnings Per Share. The EPS will grow by 48.68% on average per year.
Based on estimates for the next years, VRAX will show a very strong growth in Revenue. The Revenue will grow by 51.03% on average per year.
EPS Next Y68.42%
EPS Next 2Y48.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year477.17%
Revenue Next 2Y210.44%
Revenue Next 3Y41.9%
Revenue Next 5Y51.03%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRAX Yearly Revenue VS EstimatesVRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M 15M 20M 25M
VRAX Yearly EPS VS EstimatesVRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

VRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 24.02 indicates a rather expensive valuation of VRAX.
VRAX's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of VRAX to the average of the S&P500 Index (22.17), we can say VRAX is valued inline with the index average.
Industry RankSector Rank
PE N/A
Fwd PE 24.02
VRAX Price Earnings VS Forward Price EarningsVRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRAX Per share dataVRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VRAX's earnings are expected to grow with 48.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.68%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRAX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRAX BIOLABS GROUP LTD

NASDAQ:VRAX (6/3/2025, 11:45:54 AM)

0.98

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners6.72%
Inst Owner ChangeN/A
Ins Owners6.63%
Ins Owner ChangeN/A
Market Cap4.25M
AnalystsN/A
Price TargetN/A
Short Float %2.75%
Short Ratio0.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 24.02
P/S 50.1
P/FCF N/A
P/OCF N/A
P/B 0.49
P/tB 0.49
EV/EBITDA N/A
EPS(TTM)-2.6
EYN/A
EPS(NY)0.04
Fwd EY4.16%
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0.02
BVpS1.99
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.69%
ROE -76.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.58%
FCFM N/A
ROA(3y)-1199.47%
ROA(5y)-1754.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 289.12%
Cap/Sales 829.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.58
Quick Ratio 11.39
Altman-Z 3.21
F-Score4
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.81%
EPS Next Y68.42%
EPS Next 2Y48.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.06%
Revenue growth 3Y9.23%
Revenue growth 5YN/A
Sales Q2Q%-93.46%
Revenue Next Year477.17%
Revenue Next 2Y210.44%
Revenue Next 3Y41.9%
Revenue Next 5Y51.03%
EBIT growth 1Y10.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-70.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.46%
OCF growth 3YN/A
OCF growth 5YN/A